Drug
Befotertinib clinical trials
Also written D-0316.
- studies test it
- 10
- open now
- 5
- in phase 3
- 1
- first study started
- 2018
Keep track of what changes. Save the befotertinib studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Name
Development codes
Studies by the year they started
10 studies that test it; most in 2024 (3)
| Year | Studies |
|---|---|
| 2018 | 1 |
| 2019 | 2 |
| 2020 | 1 |
| 2021 | 1 |
| 2024 | 3 |
| 2025 | 1 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 2
- Phase 2
- 7
- Phase 3
- 1
- Phase 4
- 1
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 6 · Other 4
Betta Pharmaceuticals Co., Ltd. (4) · InventisBio Co., Ltd (2) · Hebei Medical University Fourth Hospital (1) · Second Affiliated Hospital, School of Medicine, Zhejiang University (1) · Fudan University (1) · Sun Yat-sen University (1)
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses befotertinib is read from its arms, and is right about nine times in ten.
Testing it · 10
- ctDNA Monitoring Guides the Treatment of NSCLC With Befotertinib Combined With RadiotherapyNot yet recruitingPhase 2Hebei Medical University Fourth HospitalNCT07410611Written as Befotertinib
- Sequential Chemotherapy With Befotertinib in Non-Small Cell Lung Cancer (NSCLC) Patients With Resistance to Third-Generation EGFR-TKIRecruitingPhase 2Betta Pharmaceuticals Co., Ltd.NCT07181499Written as Befotertinib
- Phase II Clinical Study of Befotertinib in EGFR Non-classical Mutant NSCLCRecruitingPhase 2Second Affiliated Hospital, School of Medicine, Zhejiang UniversityNCT06863506Written as befotertinib
- Befotertinib Adjuvant Therapy in Stage IA2-IB NSCLC PatientsRecruitingPhase 4Fudan UniversityNCT06561620Written as Befotertinib
- Befotertinib and Icotinib for NSCLC With Uncommon EGFR MutationsRecruitingPhase 2Sun Yat-sen UniversityNCT06517953Written as Befotertinib
- D-0316 Versus Icotinib in Patients With Locally Advanced or Metastatic EGFR Sensitising Mutation Positive NSCLCCompletedPhase 2/3Betta Pharmaceuticals Co., Ltd.NCT04206072Written as D-0316 Capsule
- Befotertinib and Icotinib in Treatment-naive Patients With Advanced EGFR-Mutant Lung CancerActive, not recruitingPhase 2Betta Pharmaceuticals Co., Ltd.NCT05007938Written as Befotertinib
- D-0316 in Patients With EGFR Positive Non Small Cell Lung CancerCompletedPhase 2InventisBio Co., LtdNCT03861156Written as D-0316
- D-0316 First Time in Patients Ascending Dose StudyCompletedPhase 1InventisBio Co., LtdNCT03452150Written as D-0316
- The Absorption, Metabolism and Excretion of [14C]D-0316 in HumanStatus unknownPhase 1Betta Pharmaceuticals Co., Ltd.NCT04464551Written as [14C]D-0316 suspension
Given in every arm · 1 — befotertinib is usual care beside what is tested
Codes
What other systems call befotertinib · ClinicalTrials.gg INT002119
- UNII (FDA) 0XT2CPR891BEFOTERTINIBOne source FDA
- NCI Thesaurus C175747BefotertinibOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | 0XT2CPR891 | BEFOTERTINIB | One source FDA |
| NCI Thesaurus | C175747 | Befotertinib | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.